Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Pyloric Obstruction01:11

Pyloric Obstruction

Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS).

British journal of cancer·2026
Same author

Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.

NPJ breast cancer·2025
Same author

Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial.

The British journal of surgery·2025
Same author

A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

Breast (Edinburgh, Scotland)·2025
Same author

Acute and Late Radiation-Related Toxicity After Treatment of Locally Advanced Rectal Cancer With Intensity Modulated Radiation Therapy Compared With 3-Dimensional Conformal Radiation Therapy in the RAPIDO Trial.

International journal of radiation oncology, biology, physics·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Gastric cancer.

Henk H Hartgrink1, Edwin P M Jansen, Nicole C T van Grieken

  • 1Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.

Lancet (London, England)
|July 24, 2009
PubMed
Summary
This summary is machine-generated.

Gastric cancer prevention and personalized treatment are key to reducing mortality. Strategies involve risk factors like Helicobacter pylori and gene variations, alongside updated surgical and chemotherapy approaches.

More Related Videos

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Related Experiment Videos

Last Updated: Jun 21, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Area of Science:

  • Oncology
  • Gastroenterology
  • Public Health

Background:

  • Gastric cancer is a leading cause of cancer death globally, with significant geographical incidence variations.
  • Current treatment modalities, including surgery, have limitations in improving survival and locoregional control for advanced stages.
  • Personalized treatment and prevention strategies are crucial for reducing gastric cancer mortality.

Purpose of the Study:

  • To provide an updated overview of gastric cancer incidence, causes, and pathology.
  • To review current and novel treatment strategies for gastric cancer, including surgical techniques and neoadjuvant/adjuvant therapies.
  • To explore the impact of caseload on patient outcomes and the potential of gene signatures in treatment.

Main Methods:

  • Review of current literature on gastric cancer epidemiology, risk factors, and treatment outcomes.
  • Analysis of established and emerging therapeutic approaches, such as minimally invasive surgery, chemotherapy, radiotherapy, and targeted gene therapies.
  • Examination of factors influencing patient outcomes, including the role of specialized cancer centers.

Main Results:

  • Gastric cancer incidence varies geographically, necessitating tailored prevention strategies based on Helicobacter pylori, host genetics, precursor lesions, and environmental factors.
  • While surgery is the cornerstone, its efficacy for advanced disease is limited; minimally invasive techniques are suitable for early stages.
  • Novel strategies involving neoadjuvant/adjuvant therapies, gene signatures, and the influence of caseload show promise for improving patient outcomes.

Conclusions:

  • Effective gastric cancer management requires a multi-faceted approach combining personalized prevention and advanced treatment strategies.
  • Further research into gene signatures and the impact of treatment volume is essential for optimizing patient survival and quality of life.
  • Integrating novel therapeutic modalities and understanding risk profiles are critical for reducing the global burden of gastric cancer.